company background image
A156100 logo

L&K Biomed KOSDAQ:A156100 Stock Report

Last Price

₩6.09k

Market Cap

₩125.6b

7D

2.4%

1Y

-37.9%

Updated

04 Jun, 2025

Data

Company Financials

L&K Biomed (A156100) Stock Overview

A medical company, manufactures and sells spinal implants worldwide. More details

A156100 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health3/6
Dividends0/6

A156100 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

L&K Biomed Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for L&K Biomed
Historical stock prices
Current Share Price₩6,090.00
52 Week High₩10,190.00
52 Week Low₩5,800.00
Beta1.97
1 Month Change-10.18%
3 Month Change-10.31%
1 Year Change-37.92%
3 Year Change-56.65%
5 Year Change-25.73%
Change since IPO-48.82%

Recent News & Updates

L&K Biomed Ltd.'s (KOSDAQ:156100) Price Is Out Of Tune With Revenues

Dec 16
L&K Biomed Ltd.'s (KOSDAQ:156100) Price Is Out Of Tune With Revenues

Is L&K Biomed (KOSDAQ:156100) Using Too Much Debt?

Oct 24
Is L&K Biomed (KOSDAQ:156100) Using Too Much Debt?

Recent updates

L&K Biomed Ltd.'s (KOSDAQ:156100) Price Is Out Of Tune With Revenues

Dec 16
L&K Biomed Ltd.'s (KOSDAQ:156100) Price Is Out Of Tune With Revenues

Is L&K Biomed (KOSDAQ:156100) Using Too Much Debt?

Oct 24
Is L&K Biomed (KOSDAQ:156100) Using Too Much Debt?

L&K Biomed Ltd. (KOSDAQ:156100) Investors Are Less Pessimistic Than Expected

Aug 12
L&K Biomed Ltd. (KOSDAQ:156100) Investors Are Less Pessimistic Than Expected

Revenues Tell The Story For L&K Biomed Ltd. (KOSDAQ:156100)

Apr 16
Revenues Tell The Story For L&K Biomed Ltd. (KOSDAQ:156100)

L&K Biomed (KOSDAQ:156100) Is Making Moderate Use Of Debt

Mar 09
L&K Biomed (KOSDAQ:156100) Is Making Moderate Use Of Debt

A Look At The Fair Value Of L&K Biomed Ltd. (KOSDAQ:156100)

Nov 24
A Look At The Fair Value Of L&K Biomed Ltd. (KOSDAQ:156100)

Shareholder Returns

A156100KR Medical EquipmentKR Market
7D2.4%-0.2%2.3%
1Y-37.9%-3.8%-1.6%

Return vs Industry: A156100 underperformed the KR Medical Equipment industry which returned -3.8% over the past year.

Return vs Market: A156100 underperformed the KR Market which returned -1.6% over the past year.

Price Volatility

Is A156100's price volatile compared to industry and market?
A156100 volatility
A156100 Average Weekly Movement4.0%
Medical Equipment Industry Average Movement7.3%
Market Average Movement6.2%
10% most volatile stocks in KR Market12.4%
10% least volatile stocks in KR Market3.0%

Stable Share Price: A156100 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A156100's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200891Guk-jin Kangwww.lnkbiomed.com

L&K Biomed Ltd., a medical company, manufactures and sells spinal implants worldwide. It offers anterior and expandable lateral lumber cage systems; cervical interbody fusion cage, anterior cervical plate system, posterior cervical fixation system; spinal fixation screw, lumber plate, and spinal fixation systems, as well as posterior lumber interbody cage. The company also provides lateral and anterior lumber interbody cage, and transforaminal lumber interbody cage; MIS spinal and spinal fixation systems; and SI joint fusion system.

L&K Biomed Ltd. Fundamentals Summary

How do L&K Biomed's earnings and revenue compare to its market cap?
A156100 fundamental statistics
Market cap₩125.60b
Earnings (TTM)₩5.58b
Revenue (TTM)₩35.86b
21.8x
P/E Ratio
3.4x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A156100 income statement (TTM)
Revenue₩35.86b
Cost of Revenue₩6.38b
Gross Profit₩29.48b
Other Expenses₩23.90b
Earnings₩5.58b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)279.78
Gross Margin82.21%
Net Profit Margin15.55%
Debt/Equity Ratio61.0%

How did A156100 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/04 09:58
End of Day Share Price 2025/06/04 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

L&K Biomed Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jongsun ParkEugene Investment & Securities Co Ltd.
Kyung Jun MoonMERITZ Securities Co., Ltd.
Jiwoo BaekShinhan Investment Corp.